Safety of intravitreal metoprolol in eyes with central serous chorioretinopathy.

IF 2.6 4区医学 Q2 OPHTHALMOLOGY Documenta Ophthalmologica Pub Date : 2022-12-01 DOI:10.1007/s10633-022-09895-7

Annelise Nicotti Gonçalves, André Messias, Leandro Chaves, Thaís Marino de Azeredo Bastos, Rodrigo Jorge

{"title":"Safety of intravitreal metoprolol in eyes with central serous chorioretinopathy.","authors":"Annelise Nicotti Gonçalves, André Messias, Leandro Chaves, Thaís Marino de Azeredo Bastos, Rodrigo Jorge","doi":"10.1007/s10633-022-09895-7","DOIUrl":null,"url":null,"abstract":"Purpose: To investigate ocular safety of intravitreal metoprolol in eyes with central serous chorioretinopathy.Methods: Five eyes of five patients diagnosed with chronic central serous chorioretinopathy (cCSC) previously treated unsuccessfully with oral spironolactone, micropulse laser and intravitreal anti-vascular endothelial growth factor agents were enrolled and received off-label intravitreal metoprolol (50 µg/0.05 ml). Baseline and follow-up examinations included measurement of best-corrected visual acuity (BCVA), intraocular pressure, anterior chamber cellular/flare scores, vitritis classification, fluorescein and indocyanine green angiography, spectral domain optical coherence tomography and electroretinography (ERG), recorded by means of DTL electrodes and following the standard suggested by the International Society for Clinical Electrophysiology of Vision (ISCEV). The total follow-up period was 4 weeks.Results: There were no significant differences between baseline and follow-up ERG parameters: scotopic or photopic, a- and b-wave amplitude and implicit time, nor oscillatory potentials amplitude, or whatsoever. No intraocular inflammation sign was observed. In addition, BCVA showed small improvement in 4 or kept baseline values in 1 patient. The subretinal and/or intraretinal fluid volume reduced in all patients at 1 month after treatment.Conclusion: Patients with refractory cCSC treated with intravitreal 50 µg/0.05 ml metoprolol showed no signs of acute ocular toxicity, along with intraretinal fluid reduction and slight BCVA improvement 1 month after injection. This data suggest that intravitreal metoprolol may be a safe alternative for cCSC.","PeriodicalId":11207,"journal":{"name":"Documenta Ophthalmologica","volume":"145 3","pages":"211-219"},"PeriodicalIF":2.6000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Documenta Ophthalmologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10633-022-09895-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Purpose: To investigate ocular safety of intravitreal metoprolol in eyes with central serous chorioretinopathy.

Methods: Five eyes of five patients diagnosed with chronic central serous chorioretinopathy (cCSC) previously treated unsuccessfully with oral spironolactone, micropulse laser and intravitreal anti-vascular endothelial growth factor agents were enrolled and received off-label intravitreal metoprolol (50 µg/0.05 ml). Baseline and follow-up examinations included measurement of best-corrected visual acuity (BCVA), intraocular pressure, anterior chamber cellular/flare scores, vitritis classification, fluorescein and indocyanine green angiography, spectral domain optical coherence tomography and electroretinography (ERG), recorded by means of DTL electrodes and following the standard suggested by the International Society for Clinical Electrophysiology of Vision (ISCEV). The total follow-up period was 4 weeks.

Results: There were no significant differences between baseline and follow-up ERG parameters: scotopic or photopic, a- and b-wave amplitude and implicit time, nor oscillatory potentials amplitude, or whatsoever. No intraocular inflammation sign was observed. In addition, BCVA showed small improvement in 4 or kept baseline values in 1 patient. The subretinal and/or intraretinal fluid volume reduced in all patients at 1 month after treatment.

Conclusion: Patients with refractory cCSC treated with intravitreal 50 µg/0.05 ml metoprolol showed no signs of acute ocular toxicity, along with intraretinal fluid reduction and slight BCVA improvement 1 month after injection. This data suggest that intravitreal metoprolol may be a safe alternative for cCSC.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

玻璃体内注射美托洛尔治疗中枢性浆液性脉络膜视网膜病变的安全性。

目的:探讨玻璃体内注射美托洛尔治疗中枢性浆液性脉络膜视网膜病变的安全性。方法:5例诊断为慢性中心性浆液性绒毛膜视网膜病变(cCSC)的患者，既往口服旋内酯、微脉冲激光和玻璃体内抗血管内皮生长因子治疗失败，5只眼接受超标签玻璃体内美托洛尔(50µg/0.05 ml)治疗。基线和随访检查包括测量最佳矫正视力(BCVA)、眼压、前房细胞/耀斑评分、玻璃体炎分类、荧光素和吲吲青绿血管造影、光谱域光学相干断层扫描和视网膜电图(ERG)，采用DTL电极记录，并遵循国际临床视觉电生理学会(ISCEV)建议的标准。随访时间为4周。结果:基线和随访的ERG参数无显著差异:暗位或光位，a波和b波振幅和隐式时间，也没有振荡电位振幅，或其他。未见眼内炎症征象。此外，4例患者BCVA略有改善，1例患者BCVA维持基线值。治疗后1个月，所有患者的视网膜下和/或视网膜内液量均减少。结论:玻璃体内注射50µg/0.05 ml美托洛尔1个月后，难治性cCSC患者未出现急性眼毒性，且视网膜内液减少，BCVA略有改善。这些数据提示玻璃体内美托洛尔可能是cCSC的安全选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Documenta Ophthalmologica 医学-眼科学

CiteScore

3.50

自引率

21.40%

发文量

审稿时长

>12 weeks

期刊介绍： Documenta Ophthalmologica is an official publication of the International Society for Clinical Electrophysiology of Vision. The purpose of the journal is to promote the understanding and application of clinical electrophysiology of vision. Documenta Ophthalmologica will publish reviews, research articles, technical notes, brief reports and case studies which inform the readers about basic and clinical sciences related to visual electrodiagnosis and means to improve diagnosis and clinical management of patients using visual electrophysiology. Studies may involve animals or humans. In either case appropriate care must be taken to follow the Declaration of Helsinki for human subject or appropriate humane standards of animal care (e.g., the ARVO standards on Animal Care and Use).